---
schema_version: "secwatch.filing_event.v1"
accession: "0001213900-24-066630"
form_type: "8-K"
ticker: "NKTR"
cik: "0000906709"
company_name: "NEKTAR THERAPEUTICS"
filed_at: "2024-08-08T23:59:59+00:00"
generated_at: "2026-05-31T11:31:17.542811+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.65
calibrated_materiality_score: 0.65
confidence: "high"
source: SEC EDGAR
---

# Nektar Q2 net loss $52.4M, cash $290.6M, rezpegaldesleukin Phase 2b on track for H1 2025 topline

## Summary
- Net loss Q2 2024 $52.4M ($0.25/share) vs $51.1M ($0.27) Q2 2023; non-GAAP net loss $39.1M ($0.19).
- Cash and investments $290.6M at June 30, 2024, down from $329.4M at Dec 31, 2023; runway into Q3 2026.
- Revenue Q2 2024 $23.5M vs $20.5M Q2 2023; R&D expense flat at $29.7M; non-cash restructuring/impairment $13.3M.
- Rezpegaldesleukin Phase 2b enrollment on track; topline data expected H1 2025 (atopic dermatitis) and mid-2025 (alopecia areata).

## SEC filing metadata
- accession: 0001213900-24-066630
- form_type: 8-K
- ticker: NKTR
- cik: 0000906709
- company_name: NEKTAR THERAPEUTICS
- filed_at: 2024-08-08T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.65
- calibrated_materiality_score: 0.65
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/906709/000121390024066630/0001213900-24-066630-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/906709/000121390024066630/ea0210855-8k_nektar.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001213900-24-066630
- JSON: https://secwatch.observer/filing/0001213900-24-066630.json
- Plain text: https://secwatch.observer/filing/0001213900-24-066630.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.